Brilliant Violet 785™ anti-mouse CD45.2

Catalog # / Size: 1149195 / 50 μg

Clone: 104

Isotype: Mouse IgG2a, κ

Immunogen: B10.S mouse thymocytes and

splenocytes

Reactivity: Mouse

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 785™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 785™ and


unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Concentration: 0.2



C57BL/6 mouse splenocytes were stained with CD45.2 (clone 104) Brilliant Violet 785™ (filled histogram), or mouse IgG2a, κ Brilliant Violet 785™ isotype control (open histogram).

Applications: Flow Cytometry

Recommended

Applications:

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 microg per million cells in 100 microL volume or 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, *in vivo* and *in vitro* blocking of B cell responses^{1,2}, and immunohistochemical staining of acetone-fixed frozen sections3.

Application References:

- 1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
- 2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
- 3. Suzuki K, *et al.* 2000. *Immunity* 13:691. (IHC)
- 4. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
- 5. Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837.

- 6. Pascal V, et al. 2007. J. Immunol. 179:1751.
- 7. Burman AC, et al. 2007. Blood 110:1064.
- 8. Kincaid EZ, et al. 2007. J. Immunol. 179:3187.
- 9. Phan TG, et al. 2007. Nature Immunol. 8:992.
- 10. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed
- 11. Wen T, et al. 2013. PNAS. 110:6067. PubMed
- 12. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed

Description:

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Antigen References:

1. Suzuki K, et al. 2000. Immunity 13:691.